Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients

Citation
A. Fukuda et al., Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients, CYTOK CELL, 6(3), 2000, pp. 149-154
Citations number
39
Categorie Soggetti
Medical Research Diagnosis & Treatment
Journal title
CYTOKINES CELLULAR & MOLECULAR THERAPY
ISSN journal
13684736 → ACNP
Volume
6
Issue
3
Year of publication
2000
Pages
149 - 154
Database
ISI
SICI code
1368-4736(200009)6:3<149:EOIOPN>2.0.ZU;2-6
Abstract
Granulocytopenia is commonly observed in interferon-alpha (IFN-alpha) thera py. Granulocyte colony-stimulating factor (G-CSF) has been identified as a primary cytokine that regulates neutrophil production, but the kinetics of G-CSF in IFN-alpha -induced granulocytopenia remains unclear. We investigat ed the effects of IFN-alpha on serum G-CSF levels and peripheral neutrophil counts (NC) in 15 chronic hepatitis C patients treated with standard-dose (10 MU) recombinant IFN-alpha for 24 weeks by using a chemiluminescent enzy me immunoassay for G-CSF. The time course of change after a single lFN-alph a injection showed that mean serum G-CSF levels and NC increased significan tly compared with pretreatment values (p < 0.05), and were statistically co rrelated (r = 0.914, p = 0.0015). On repeating IFN-<alpha> administration, this change gradually became unclear, and granulocytopenia occurred, accomp anied by a significant increase in serum G-CSF (p < 0.01). Both values reac hed a plateau within 2 weeks after starting treatment, and recovered rapidl y after the cessation of therapy. Although continuous administration of IFN -<alpha> caused a time-dependent granulocytopenia, our results suggest that a single injection of IFN-alpha would be a potent inducer of G-CSF and NC in vivo as a short-term effect and that there would be negative-feedback re gulation between them during long-term IFN-alpha therapy.